---
title: "Bruce C. Cozadd, Chairman & CEO of Jazz Pharmaceuticals, Reports Disposal of Common Shares"
description: "Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generate"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238803917.md"
published_at: "2025-05-05T23:01:14.000Z"
---

# Bruce C. Cozadd, Chairman & CEO of Jazz Pharmaceuticals, Reports Disposal of Common Shares

> Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

Bruce C. Cozadd, the Chairman and CEO of Jazz Pharmaceuticals plc, reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001765581-25-000039), on May 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [JAZZ.US - Jazz Pharma](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results | Jazz Pharmaceuticals (JAZZ) has gained attention following positive Phase 3 results for its HER2-targeted drug Ziihera i | [Link](https://longbridge.com/en/news/271933572.md) |
| What Analysts Are Saying About Jazz Pharmaceuticals Stock | Analysts have provided mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months, with 11 analysts | [Link](https://longbridge.com/en/news/272265895.md) |
| Jazz Pharmaceuticals Showcases Rare Disease Breakthroughs and Growth Strategy in New Presentation | Jazz Pharmaceuticals plc presented at the 44th Annual J.P. Morgan Healthcare Conference, showcasing its achievements and | [Link](https://longbridge.com/en/news/272449426.md) |
| Jazz Pharmaceuticals Completes Acquisition of Chimerix | Jazz Pharmaceuticals has acquired Chimerix, integrating it into its corporate strategy. The acquisition includes the Pha | [Link](https://longbridge.com/en/news/272282470.md) |
| Jazz Pharmaceuticals Announce Positive Efficacy From Ziihera Phase 3 Trial | Jazz Pharmaceuticals PLC :ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOC | [Link](https://longbridge.com/en/news/271691426.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.